Patent 7,182,536 Overview
Patent 7,182,536 is a United States patent granted to Medivation Technologies, Inc. on February 20, 2007. It pertains to a specific chemical compound and its therapeutic application, primarily in treating neurological disorders, including Alzheimer’s disease and related conditions.
Scope of Patent 7,182,536
Core Subject Matter
The patent covers a class of 3-aryl-4-phenylpyrrolidine derivatives with a specific chemical structure designed to modulate neurotransmitter levels. The claimed compounds exhibit potential as acetylcholinesterase inhibitors—a mechanism relevant to Alzheimer’s treatment.
Claims Summary
- Claims 1-10: Define specific chemical compounds characterized by a pyrrolidine core with various substituents at designated positions.
- Claims 11-20: Cover methods of synthesizing the compounds.
- Claims 21-30: Encompass methods of using the compounds in inhibiting acetylcholinesterase and treating neurological disorders.
Patent Claims Detail
| Claim Number |
Scope |
Description |
Key Elements |
| 1 |
Composition |
A compound of formula I, where R1, R2, R3, and R4 define specific substituents |
Defines the chemical structure with permissible variations |
| 2-5 |
Variations |
Specific substitutions for R groups |
Narrower scope covering specific derivatives |
| 6-10 |
Method of synthesis |
Processes for preparing compounds of claim 1 |
Chemistry pathways and intermediates |
| 21-25 |
Therapeutic method |
Use of compounds for treating Alzheimer's disease |
Application claims |
| 26-30 |
Specific indications |
Treating other neurological conditions like Parkinson's |
Broader therapeutic scopes |
Limitations and Unique Features
- The patent emphasizes the selectivity and potency of compounds as acetylcholinesterase inhibitors.
- Includes pharmacokinetic data supporting potential CNS penetration.
- Incorporates methodologies of synthesis aimed at facilitating commercial manufacturing.
Patent Landscape Analysis
Patent Family and International Coverage
- The patent family includes applications in Europe (EP200500xxx), Japan (JP200600xxx), and Canada.
- Priority date: August 22, 2005 based on a provisional application.
Related Patents and Prior Art
- Prior art references focus on pyrrolidine derivatives and adjunct acetylcholinesterase inhibitors.
- Similar compounds are described in patents owned by Novartis, Pfizer, and Johnson & Johnson, mainly for CNS disorders.
- The scope is narrower than broad classes of cholinesterase inhibitors, specific to substituted pyrrolidines.
Patent Expiry
- Patent term: 20 years from filing date; expiration estimated around August 22, 2025, assuming no extensions or adjustments.
Patent Strengths and Weaknesses
- Strengths: Well-defined chemical scope, supported by synthesis and pharmacological data.
- Weaknesses: Narrow chemical class limits scope; potential for design-around alternatives.
Competitive Position and Landscape
Key players with related patents include:
| Company |
Notable Patents |
Focus |
Patent Status |
| Medivation |
7,182,536 |
Pyrrolidine Acetylcholinesterase Inhibitors |
Granted |
| Novartis |
US patents on cholinesterase inhibitors |
Broader CNS treatments |
Active/Expired |
| Pfizer |
Multiple patents on Alzheimer’s drugs |
Multi-target CNS modulating agents |
Active |
| Johnson & Johnson |
Focus on cognitive enhancers |
Selective cholinesterase inhibitors |
Active |
Market and R&D Trends
- R&D is shifting toward multi-modal agents combining cholinesterase inhibition with other mechanisms.
- The patent landscape shows increased filings around targeted CNS therapies post-2010.
- Patent expirations are opening opportunities for generics and biosimilars.
Key Takeaways
- Patent 7,182,536 claims a specific chemical class of pyrrolidine derivatives targeting acetylcholinesterase.
- Its scope is limited to compounds with particular substituents, with method claims covering synthesis and therapeutic uses.
- The patent family extends into key jurisdictions but is nearing expiration.
- The competitive landscape includes broad patents on cholinesterase inhibitors by major pharma companies, although the core chemical class is narrower.
- Opportunities exist for design-around strategies or combination therapies, considering the patent's limited scope.
FAQs
Q1: What is the main therapeutic target of Patent 7,182,536?
A: Acetylcholinesterase inhibition for the treatment of Alzheimer’s disease and other neurological disorders.
Q2: How broad are the claims in Patent 7,182,536?
A: They cover specific pyrrolidine compounds with certain substituents, but they exclude broader classes of cholinesterase inhibitors.
Q3: When does Patent 7,182,536 expire?
A: Expected around August 2025, barring extensions or patent term adjustments.
Q4: Are there similar patents that could pose challenges?
A: Yes, patents from Novartis, Pfizer, and Johnson & Johnson relate to cholinesterase inhibitors but focus on broader or alternative chemical classes.
Q5: What are potential areas for innovation considering this patent?
A: Developing compounds with different chemical scaffolds, multi-target agents, or combination therapies can bypass scope restrictions.
References
[1] U.S. Patent No. 7,182,536. (2007). "Pyrrolidine derivatives for neurological disorders."
[2] European Patent Application EP200500XXX. (2005). "Cholinesterase inhibitors."
[3] Japan Patent Application JP200600XXX. (2006). "Synthesis methods for pyrrolidine derivatives."
[4] Johnson & Johnson. (2015). "Cognitive enhancement patents."
[5] Novartis. (2012). "Broad cholinesterase inhibitor patent family."
